Clinical trial
Feasibility of Study of Empagliflozin in Patients With Autosomal Dominant Polycystic Kidney Disease
NCT05510115 is registered in ClinicalTrials.gov with University of Colorado, Denver as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Feasibility of Study of Empagliflozin in Patients With Autosomal Dominant Polycystic Kidney Disease
- Lead sponsor
- University of Colorado, Denver
- Phase
- Phase 2
- Overall status
- Active, not recruiting
- Start date
- November 18, 2022
- Completion date
- August 1, 2026
- Enrollment
- 50 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.